Hjem › Kolorektal kreft › North Carolina › Durham
Kliniske studier for Kolorektal kreft i Durham, NC
28 studier for Kolorektal kreft søker deltakere på steder i og rundt Durham (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
RekruttererFase 3
- Duke University Medical Center /ID# 279322, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- Duke University, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Durham VA Medical Center, Durham
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
- Exelixis Clinical Site #12, Durham
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RekruttererFase 3
- Duke Cancer Center - Investigational Chemotherapy Service, Durham
- Duke Cancer Center, Durham
- Duke University Hospital - Vascular Interventional Radiology, Durham
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
RekruttererFase 1/2
- Duke Cancer Center, Durham
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
RekruttererFase 2
- University of North Carolina Medical Center /ID# 267786, Chapel Hill · 10 mi unna
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
RekruttererFase 3
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
RekruttererFase 3
- Duke University Medical Center, Durham
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekruttererFase 1
- Duke University Medical Center, Durham
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
RekruttererFase 1/2
- Duke University Medical Center, Durham
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RekruttererFase 1/2
- Duke University School of Medicine, Durham
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
RekruttererFase 3
- The University of North Carolina At Chapel Hill, Chapel Hill · 10 mi unna
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
RekruttererFase 3
- Duke Cancer Center, Durham
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
RekruttererFase 1
- Duke University Medical Center, Durham
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
RekruttererFase 2
- Duke University Medical Center - Duke Cancer Center, Durham
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- Duke University, Durham
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
RekruttererFase 1/2
- GSK Investigational Site, Durham
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
RekruttererFase 1
- Duke Cancer Center, Durham
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
RekruttererFase 3
- Duke University Hospital, Durham
- Duke University Medical Center, Duke Cancer Center, Durham
- Duke University Medical Center, Durham
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
RekruttererFase 2
- Duke University Medical Center, Durham
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Rekrutterer
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 10 mi unna
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RekruttererFase 2
- Duke University Medical Center /ID# 279457, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RekruttererFase 1
- Research Site, Durham
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
RekruttererFase 1/2
- Duke University Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RekruttererFase 1
- Duke Cancer Center, Durham
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Rekrutterer
- Duke Cancer Institute, Durham
Kolorektal kreft-studier i andre byer
- Houston, TX102 studier
- New York City, NY78 studier
- Nashville, TN69 studier
- Boston, MA63 studier
- Los Angeles, CA59 studier
- Arlington, VA52 studier
- St. Louis, MO50 studier
- San Antonio, TX46 studier
- Philadelphia, PA44 studier
- Grand Rapids, MI40 studier
- Baldwin Park, CA37 studier
- Chicago, IL34 studier
Andre studier i Durham
- Brystkreft64 studier
- Kreft (alle typer)58 studier
- Ikke-småcellet lungekreft39 studier
- Multipelt myelom37 studier
- Akut myelogen leukemi33 studier
- Metastatisk kreft33 studier
- Prostatakreft32 studier
- Lungekreft32 studier
- Eggstokkreft27 studier
- Kronisk lymfatisk leukemi27 studier
- Hjertesvikt26 studier
- Pankreaskreft24 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.